Wendel Christopher, Kaech Denis Laurent, Woodtli Martin
Department of Neurosurgery, Katharinenhospital, Stuttgart, Germany.
Department of Neurosurgery, KSGR, Chur, Switzerland.
J Neurol Surg A Cent Eur Neurosurg. 2018 Jul;79(4):344-352. doi: 10.1055/s-0038-1639504. Epub 2018 Apr 12.
Primary pineal malignant melanoma is a rare type of primary central nervous system melanoma with only 19 cases reported in the literature.
We present a case of a 53-year-old man with primary melanoma of the pineal region. He presented to the emergency department with gait unsteadiness and ataxia. Magnetic resonance imaging (MRI) revealed a 22 × 17 × 22-mm mass in the pineal region. On MRI the tumor was hyperintense in T1, isointense in T2, and on T1-weighted images with gadolinium enhancement it appeared homogeneously hyperintense with hypointense spots. Our patient underwent subtotal tumor resection as well as radiotherapy. The 52-week MRI control showed no recurrence of the lesion.After 62 weeks he developed gait ataxia and headaches and was admitted to the emergency department. Computed tomography revealed tumor bleeding and obstructive hydrocephalus.An external ventricular drain was placed, but the bleeding progressed, and 7 days after admission, MRI showed bleeding in the thalamus and mesencephalon. With a dismal prognosis, therapy was discontinued. He died 65 weeks after diagnosis.
We reviewed the available literature (PubMed) with 19 published cases of primary pineal malignant melanoma and evaluated the common symptoms at presentation, histopathologic features, radiologic findings, therapeutic regimens, and time of survival to provide the most up-to-date treatment.
The median age of patients with primary pineal malignant melanoma is 52 years (female-to-male ratio: 10:10 years); a common first sign is chronic hydrocephalus. On MRI the lesion presents hyperintense in T1 and hypo- to isointense in T2. Biopsy or resection and histopathologic analysis are the key to diagnosis. Common histopathologic features are melanic pigment ( = 19/20), positive Human Melanoma Black (HMB-45) marker ( = 13/20), positive S100 protein reactivity ( = 11/20), as well as positive Melan-A ( = 9/20). The median survival was > 56.5 weeks in patients treated with resection and radiation.
Reconsidering the reported cases surgical treatment followed by radiation increases the length of survival.
原发性松果体恶性黑色素瘤是原发性中枢神经系统黑色素瘤的一种罕见类型,文献中仅报道了19例。
我们报告一例53岁男性原发性松果体区黑色素瘤患者。他因步态不稳和共济失调就诊于急诊科。磁共振成像(MRI)显示松果体区有一个22×17×22毫米的肿块。在MRI上,肿瘤在T1加权像上呈高信号,在T2加权像上呈等信号,注射钆对比剂后T1加权像上呈均匀高信号,伴有低信号灶。我们的患者接受了肿瘤次全切除及放疗。52周的MRI复查显示病变无复发。62周后,他出现步态共济失调和头痛,再次入住急诊科。计算机断层扫描显示肿瘤出血和梗阻性脑积水。放置了外部脑室引流管,但出血仍在进展,入院7天后,MRI显示丘脑和中脑出血。由于预后不佳,停止了治疗。他在诊断后65周死亡。
我们回顾了现有文献(PubMed)中19例原发性松果体恶性黑色素瘤的病例,评估了患者就诊时的常见症状、组织病理学特征、影像学表现、治疗方案及生存时间,以提供最新的治疗方法。
原发性松果体恶性黑色素瘤患者的中位年龄为52岁(男女比例为10:10);常见的首发症状是慢性脑积水。在MRI上,病变在T1加权像上呈高信号,在T2加权像上呈低信号至等信号。活检或切除及组织病理学分析是诊断的关键。常见的组织病理学特征为黑色素沉着(19/20)、人黑色素瘤黑色(HMB-45)标记物阳性(13/20)、S100蛋白反应阳性(11/20)以及Melan-A阳性(9/20)。接受手术切除及放疗的患者中位生存期>56.5周。
综合报道的病例来看,手术治疗后进行放疗可延长生存期。